Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA policy on direct-to-consumer Rx drug ads

Executive Summary

FDA's working group on direct-to-consumer advertising of prescription drugs will meet in the "near future" to review recent revisions made in a draft document outlining the agency's official policy. Before being issued for comment in the Federal Register, the policy must be approved by Center for Drug Evaluation and Research Director Carl Peck and FDA Acting Commissioner James Benson. FDA's Division of Drug Advertising and Labeling recently submitted documents to Rep. Dingell regarding FDA's position on direct-to-consumer prescription ads ("The Pink Sheet" April 9, p. 5).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017297

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel